https://www.thebodypro.com/category/fda-approved-hiv-medications

FDA-Approved HIV Medications

The Latest

Unintended Pregnancies With Levonorgestrel Implant Due to Drug Interactions With Efavirenz-Based Antiretroviral Therapy Img
Conference Coverage

Unintended Pregnancies With Levonorgestrel Implant Due to Drug Interactions With Efavirenz-Based Antiretroviral Therapy

Three unintended pregnancies in women with levonorgestrel sub-dermal implants, receiving efavirenz-based antiretroviral therapy in a pharmacokinetic study, were reported in a late breaker presentation at CROI 2015.

Promo Image
IDWeek

What 2014 Development Has the Biggest Impact on HIV Care?

Each year we see new developments in HIV that improve the lives of those living with the disease and make it easier for providers to care for patients. We asked some of the leading experts what development this year they thought would have the biggest …

Promo Image
IDWeek

HIV Drug Development Pipeline Update, Fall 2014 Edition

HIV treatment remains far from perfect, and there are still seats at the table available for improved antiretrovirals. Paul Sax, M.D., provides an update on several of the most noteworthy candidates currently in development.

Promo Image
IDWeek

What's Hot in HIV Treatment

Here’s a recap of the biggest developments in HIV treatment over the past year, as well as a look at what’s to come.

Could an Integrase Inhibitor Have Prevented One More HIV Infection? Img

Could an Integrase Inhibitor Have Prevented One More HIV Infection?

Monica Gomes, M.D., M.Sc. presents a case where perhaps adding an integrase inhibitor during pregnancy may have helped prevent one more instance of mother-to-child transmission.

Promo Image
Metabolic

Long-Term Exposure to Protease Inhibitors May Increase Diabetes Risk in HIV

This article was reported by Healio.

Healio reported on a study of the effect of long-term exposure to antiretrovirals (ARVs) and increased diabetes risk in HIV-positive individuals. Researchers conducted a retrospective observational study using 19...

Promo Image

Attachment Inhibitor Shows Some Progress in Trials

Programs that have sought to develop anti-HIV drugs (of all classes) have sometimes produced candidate compounds that may appear potent in laboratory experiments with cells. However, when these compounds are later tested in people, they sometimes fai...

Kaposi's Sarcoma and HIV: Not Gone, Not Forgotten Img
Cancer

Kaposi's Sarcoma and HIV: Not Gone, Not Forgotten

Think Kaposi's sarcoma is a relic of a bygone era? A flurry of new research highlights just how relevant the disease still is -- and how much about it we have yet to learn.

Viral Load Rebound Rate of 35% Using Ritonavir-Boosted PI Monotherapy: Results of 5-Year PIVOT Study Img
Conference Coverage

Viral Load Rebound Rate of 35% Using Ritonavir-Boosted PI Monotherapy: Results of 5-Year PIVOT Study

A long-term strategy study sponsored by the Medical Research Council (MRC) in the UK reported low rates of serious complications and the potential to reduce drug costs. However, more than a third of people on the ritonavir-boosted PI monotherapy grou...

Promo Image
Conference Coverage

NNRTI Resistance Found in 12% of People Stopping Treatment With Undetectable Viral Load: Implications for Stock-Outs

Although stopping ART is not recommended, this still occurs due to drug stock-outs in some countries and retrospective data from the UK HIV Drug Resistance Database (HDRD) highlighted the risk this has for developing drug resistance.

Valentina Cambi...